Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.28), Zacks reports.
Bicara Therapeutics Price Performance
NASDAQ BCAX traded down $1.47 during mid-day trading on Tuesday, reaching $12.73. 448,375 shares of the stock were exchanged, compared to its average volume of 487,564. The stock has a 50 day simple moving average of $12.94 and a 200-day simple moving average of $15.46. Bicara Therapeutics has a one year low of $8.91 and a one year high of $28.09.
Analysts Set New Price Targets
A number of equities analysts recently commented on BCAX shares. Wells Fargo & Company started coverage on shares of Bicara Therapeutics in a research note on Thursday, April 17th. They issued an "underweight" rating and a $8.00 price objective for the company. Stifel Nicolaus set a $48.00 price objective on Bicara Therapeutics in a research report on Thursday, March 27th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $13.01 price target on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Wedbush reiterated an "outperform" rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Finally, HC Wainwright decreased their price objective on shares of Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating on the stock in a research report on Monday, April 7th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $32.43.
Read Our Latest Analysis on Bicara Therapeutics
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
